bluuebunny/crossref_metadata_2025 huggingface dataset:
Pulsed field ablation for atrial fibrillation: acute procedural efficacy and safety of an initial German multicenter experience
Authors: Gunawardene M A , Lemoine M , Deneke T , Wakili R , Steven D , Schaeffer B , Rillig A , Nentwich K , Siebermair J , Filipovic K , Simu G , Riesinger L , Sultan A , Willems S , Metzner A
Published: October 2022

Background

Pulsed field ablation (PFA) is a novel non-thermal energy source to conduct catheter ablation of atrial fibrillation (AF). However, real-world multi-center data regarding acute procedural efficacy and safety is sparse.

Purpose

To study acute procedural success and safety in patients undergoing PFA for catheter ablation of AF in a multicenter registry.

Methods

Consecutive paroxysmal and persistent AF patients undergoing PFA-based catheter ablation using a multispline catheter were enrolled. The cohort included first and repeat ablation procedures. Procedural parameters, acute success and in-hospital safety were evaluated. A follow-up of all patients was conducted.

Results

Five German centers enrolled a total of 154 patients undergoing PFA in this study. Mean age was 68±12 years, median CHA2DS2-VASc Score was 3 (Q1-Q3: 2–4).

Patients suffered from paroxysmal AF (n=55; 36%), persistent AF (n=93; 60%) and consecutive atrial tachycardias (AT) due to previous CA (n=6; 4%).

The median left atrial (LA) PFA and total procedure times were 33 (Q1-Q3: 24–53) and 90 (Q1-Q3: 73–116) minutes, respectively. Mean LA PFA fluoroscopy and total fluoroscopy times were 12.1±5.5 and 20.2±8.7 minutes. Of all 154 procedures, 130 (84%) were index ablation procedures with isolation of pulmonary veins (PVI) only and 24 (16%) were repeat procedures (including re-PVI and ablation of consecutive AT).

Acute PV reconnection following primary PVI and the initial set of PFA-applications was found in 20/130 (15%) patients, necessitating additional PFA ablation. Finally, successful PFA-guided PVI was achieved in all patients.

Additional PFA lesion sets (including LA posterior wall isolation, anterior ablation, mitral isthmus ablation) were applied in 17/154 (11%) patients.

Complications occurred in a total of 6/154 (3.8%) patients (including three groin site complications, two pericardial tamponades, one transient coronary spasm without sequela). The follow up data is still being assessed and will be provided by the time of the ESC 2022 meeting.

Conclusion

PFA performed in patients with atrial fibrillation demonstrates high acute procedural success rates and a favorable safety profile in this first real-world multicenter registry.

Funding Acknowledgement

Type of funding sources: None.
Early rapid local impedance drop is associated with acute lesion efficacy during pulmonary vein isolation using a novel contact force sensing catheter
Authors: Perge P , Sallo Z , Petrovic N , Piros K , Nagy K V , Osztheimer I , Merkely B , Geller L , Szegedi N
Published: October 2022

Introduction

The predictive role of adequate local impedance drop in lesion formation using a novel contact force sensing ablation catheter for pulmonary vein isolation was recently described. The purpose of our study was to assess the temporal characteristics of local impedance drop during ablation and its correlation with acute lesion efficacy.

Methods

Point-by-point radiofrequency pulmonary vein isolation was performed in power-controlled mode with 50 W energy setup. The efficacy of applications was determined by pacing along the circular ablation line. The successful lesions were estimated if loss of capture was achieved. Local impedance, contact force and catheter position data of the applications with 5 msec resolution was analysed. The local impedance of successful and unsuccessful applications was compared at baseline and 2, 4, 6, 8, 10 and 12 sec time points, respectively. We characterized the local impedance for each time point with the mean of the 5 impedance value closest in time. The sum of the range of catheter position in x, y and z dimensions was also compared to assess stability during the application.

Results

643 applications were analysed, 559 were successful and 84 were unsuccessful. Mean contact force was lower (p=0.04), while the sum of catheter position range was higher (p<0.001) in unsuccessful applications during ablation, suggesting worse catheter stability. The successful applications were characterized by a higher baseline local impedance (p<0.001), and a larger local impedance drop at the 2, 4, 6, 8 and 10 sec time points (p<0.001, for all). In case of unsuccessful applications, after a moderate but significant drop from baseline to the 2 sec time point (baseline: 153 Ohm vs 2 sec: 145 Ohm, p<0.001) local impedance did not change further over time (2 sec: 145 Ohm vs 12 sec: 143 Ohm; p=0.99). While on the other hand, in case of successful applications, the local impedance further decreased significantly up to the 10 sec timepoint, respectively (baseline: 161 Ohm vs 2 sec: 150 Ohm vs 10 sec: 141 Ohm, p<0.001 for all). The optimal cut-point for the local impedance drop indicating unsuccessful application was <9 Ohms at the 4 second time point [AUC=0.73 (0.67–0.76), p<0.001]. Failing to reach at least 9 Ohm impedance drop at the 4 second time point predicted unsuccessful applications [(p<0.001; OR: 3.82 (2.34–6.25)].

Conclusion

Rapid and enduring drop of the local impedance may predict effective lesion formation, while slightly changing or unchanged local impedance is associated with unsuccessful applications. In case of a moderate local impedance drop during the first 4 seconds of radiofrequency application, it might be reasonable to stop the application and start a new one after catheter repositioning.

Funding Acknowledgement

Type of funding sources: None.
Inflammation begets isolated atrioventricular conduction disturbances in young an observation from indian registry data
Authors: Moukthika K V N , Krishnappa D , Patloori Sirish Chandra S , Bhole C , Deshpande S , Roshan J , Barthur A , Parameshwaran S , Mehta R , Padmanabhan D
Published: October 2022

Background

High grade AV block is less commonly encountered in patients <60 years. The aetiological role of inflammatory conditions is not well studied in this group of patients.

Purpose

To determine the prevalence of myocardial inflammation in young patients presenting with High grade AV block and assess its response to immunosuppression.

Methodology

This is a prospective, registry based, observational study conducted at two centers from Jan 2020 to Dec 2021. Myocardial inflammation was detected using Cardiac PET, and/or histopathological examination. Those with evidence of inflammation were started on graded immunosuppression.

Results

318 patients were enrolled. Mean EF was 55.2±7.0%. Cardiac PET was performed in 87/318 (27.3%). Myocardial inflammation was seen in 57/87 (65%). LV basal septum was most commonly involved. 44/57 (77%) were started on immunosuppressive therapy after excluding indolent tuberculosis.8 patients died during follow-up with all deaths being sudden in nature. 5/44 (11.3%) had reversal of CHB with resolution of cPET findings.

Conclusion

Significant proportion of young patients with High grade AV block have segmental myocardial inflammation. Immunosuppression helps restore AV conduction in some of these patients. Long-term studies are required to assess adverse impact of inflammation on cardiac contractile function.

Funding Acknowledgement

Type of funding sources: None.
Opposite evolution on voltage and thickness from paroxysmal to persistent AF
Authors: Silva Garcia E , Banez V , Gonzalez M , Puche J E , Gomez A , Cano L , Fernandez R , Fernandez M , Fernandez-Armenta J
Published: October 2022

Background

There is a controversy about correlation between voltage and thickness in the atrial myocardium and their evolution from paroxysmal to persistent atrial fibrillation (AF).

Purpose

This is an observational study to compare voltage and thickness of different areas on the left atrium in paroxysmal and persistent atrial fibrillation.

Methods

Twenty-one patients underwent atrial fibrillation ablation. Points with electrical information from an electroanatiomical map in sinus rhythym were acquiered during the ablation procedure covering the whole atrial surface. CT was acquired in all patients before the procedure and endo- and epicardium from the atrium was segmented for the atrial thickness calculation. All the points from the electromecanical map were projected on the thickness map to have both information on the same location. 3D atrium was segmented in 5 areas for the analysis: Lateral, Anterior, Septal, Inferior-Posterior and Superior-Posterior (Figure 1). Voltage and thickness values among different areas and between AF type were compared.

Results

11 paroxysmal and 10 persistent AF patients were analyzed acquiring 452±207 points per patient and 1897±750 points per area. There was no linear correlation between voltage and thickness comparing all the patients nor among different areas nor between AF type (R<0.2 in all cases).

Regarding paroxysmal AF patients, septum showed significatly lower voltage compared with the other segments, posterior, lateral, anterior and roof (1.3±1.4, 2±1.8, 2±1.6, 1.7±1.5, 2±1.6, P<0.001). Posterior segment showed the highest voltage. The thickness analysis showed the septum segment as thinner segment and lateral as thicker segment (1.3±1.5,1.7±0.8, P<0.001) (Figure 2).

Regarding persisten AF patients: septum showed significatly lower voltage compared with the other segments, posterior, lateral, anterior and roof who shows higher voltage (1±0.8*, 1.5±1.2, 1.9±1.7, 1.5±1.4, 2±1.6) (Figure 2). The thickness analysis showed the anterior segment as thinner segment and lateral as the thickest segment (1.6±0.8, 1.9±0.9 (P<0.001), different like on paroxysmal AF population.

Comparing voltage and thicknes between paroxysmal and persistent AF, all the segments on persistent population showed lower voltage values, with significant differences on septal, posterior and anterior walls (1±0.8 vs 1.3±1.4, 1.5±1.2 vs 2±1.8, 1.5±1.4 vs 1.7±1.5, P<0.001). On the other hand, all segments on persistent population showed statisticaly signignificant thicker myocardium in camparison with paroxysmal population (Figure 2).

Conclusions

According to our findings, there is no linear correlation between voltage and thickness. Persistent AF atria show thicker walls but with lower voltages in comparison with paroxysmal AF atria.

Funding Acknowledgement

Type of funding sources: None.
Dapagliflozin but not empagliflozin prevents atrial fibrillation in an experimental whole-heart model
Authors: Frommeyer G , Uphoff J , Wolfes J , Eckardt L , Ellermann C
Published: October 2022

Background

The SGLT2 inhibitors dapagliflozin and empagliflozin have an evolving role in heart failure therapy. Observational data suggest a lower risk of atrial fibrillation (AF) for patients on SGLT2 inhibitors. So far, it is unclear whether this is related to a direct antiarrhythmic potential of SGLT2 inhibitors or just a marker of improved heart function. Experimental data on the impact of SGTL2 inhibitors on atrial electrophysiology is scarce.

Purpose

This study aimed at evaluating the effects of the two SGLT2 inhibitors dapagliflozin and empagliflozin on atrial electrophysiology.

Methods

25 rabbit hearts were explanted and retrogradely perfused employing the Langendorff-setup. Two catheters were placed on both atria to record monophasic action potentials. Hearts were paced at three different cycle lengths (350ms, 250ms, 150ms), thereby obtaining cycle-length dependent atrial action potential durations (aAPD90) and effective refractory periods (aERP). Atrial post-repolarization (aPRR) refractoriness was determined by the difference between aERP and aAPD90. AF was induced in the presence of acetylcholine (ACh, 1μM) and isoproterenol (Iso, 1μM). Thereafter, hearts were treated with dapagliflozin (n=13, 3 μM) or empagliflozin (n=12, 3 μM).

Results

Ach/Iso abbreviated aAPD90, aERP and prolonged aPRR in both groups (dapagliflozin group: aAPD90: −49 ms, p<0.01; aERP: −33 ms, p<0.01; aPRR: +18 ms, p=0.06; empagliflozin group: aAPD90: −40 ms, p<0.01; aERP: −25 ms, p<0.05; aPRR: +18 ms, p=0.05). Further treatment with dapagliflozin increased aAPD90 (+13 ms, p<0.01), aERP (+34 ms, p<0.05) and aPRR (+6 ms, p=ns). Additional administration of empagliflozin had no significant effect on aAPD90 (−8 ms, p=ns), aERP (−1 ms, p=ns) or aPRR (+9 ms, p=ns). Vulnerability to AF was assessed by a standardized protocol consisting of several trains of burst pacing. Ach/Iso increased the vulnerability to AF episodes in both groups (dapagliflozin group: 71 episodes vs. 1 under baseline conditions, p<0.01; empagliflozin group: 27 episodes vs. 2 under baseline conditions, p=0.08). Additional perfusion of dapagliflozin significantly reduced the occurrence of AF (to 30 episodes, p<0.05) while additional empagliflozin treatment had no significant antiarrhythmic effect (32 episodes, p=ns).

Conclusion

Dapagliflozin and empagliflozin had opposing effects on atrial electrophysiology. Dapagliflozin prolonged aAPD90 and aERP, thereby preventing AF. In contrast, empagliflozin did not change aAPD90 or aERP, resulting in no antiarrhythmic effect. Our findings hint at a potential antiarrhythmic benefit of dapagliflozin.

Funding Acknowledgement

Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Hans and Gertie Fischer-Foundation (to C.E.)
Sodium-glucose cotransporter 2 inhibitors not only suppress recurrence after atrial fibrillation ablation but also cause atrial reverse remodeling
Authors: Mine T , Kitagaki R , Fukuhara E , Ishihara M
Published: October 2022

Background

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown fewer heart failure (HF) hospitalization and cardiovascular death in patients with type-2 diabetes mellitus (DM). Atrial fibrillation (AF) is associated with both HF and DM, and we reported SGLT2 suppressed AF recurrence after catheter ablation (CA) than dipeptidyl peptidase-4 (DPP4) inhibitor.

Purpose

We evaluated whether SGLT2 itself induces atrial reverse remodeling.

Methods

This is a sub-analysis of a prospective randomized controlled open-label clinical study for comparing the suppressive effect of SGLT2 inhibitor with DPP4 inhibitor on AF recurrence after CA. Eighty AF patients with type-2 DM were randomized to Tofogliflozin group or Anagliptin group with a computer-generated random sequence, which was stratified by left atrial diameter and AF type at screening. Primary outcome is AF recurrence at 12 months after CA, and secondary outcomes include the echocardiographic findings.

Results

70 patients (70.3±8.1 years, 58 male, 30 paroxysmal AF, 38 Tofogliflozin) were analyzed. Recurrent AF was detected in 24 patients (34.3%), and the AF recurrence ratio was higher in the Anagliptin group than the Tofogliflozin group. In 46 patients without AF recurrence (17 Anagliptin, 29 Tofogliflozin), LAVI has shrunk in 12 months compared to the baseline (42.8±11.9 to 36.6±11.2ml/m2) and the reduction of LAVI was larger in Tofogliflozin group than Anagliptin group (−8.6±2.0ml/m2 vs. −2.0±2.6ml/m2, P=0.0471).

Conclusion

Tofogliflozin not only suppressed AF recurrence after CA but also caused atrial reverse remodeling than Anagliptin in type-2 DM patients.

Funding Acknowledgement

Type of funding sources: None.
Development of the new risk score to predict occurrence of atrial fibrillation early after acute myocardial infarction
Authors: Iwakura K , Onishi T , Okamura A , Koyama Y , Hirao Y , Tanaka K , Iwamoto M , Tanaka N , Okada M , Watanabe H , Nakatani D , Hikoso S , Sakata Y , Sakata Y
Published: October 2022

Background/Introduction

New onset of atrial fibrillation (AF) is associated with adverse short- and long-term outcomes after acute myocardial infarction (AMI), and its prediction is relevant for the risk stratification in patients with AMI. Although several risk scores were developed for AF in the general population, there is no established risk score for AF occurrence after AMI.

Purpose

To develop a risk score to predict occurrence of AF early after AMI.

Methods

We enrolled consecutive 751 patients with AMI who admitted to our hospital between April 2006 and September 2012 for the present study. New occurrence of AF was defined as AF detected during hospital stay in a patient showing normal regular sinus rhythm at admission. Parameters relevant to the occurrence of AF was selected from the clinical characteristics, physical status and blood test data at admission, and peak CK/CK-MB, by stepwise logistic regression analysis. We constructed a risk score model to predict the new occurrence of AF, using selected parameters and their logistic regression coefficients. C-statistics was determined by constructing a receiver operating characteristic curve to evaluate the accuracy of the risk score for prediction of AF occurrence.

Results

We excluded 48 patients (6.4%) who had AF at admission, and 208 patients without sufficient data at admission, and thus, the study group consisted of 459 patients (age; 65±13 years, male gender; 79.6%). New AF occurrence was observed in 72 patients (14.5%). The following 7 parameters was selected as parameters related with AF (as p<0.1); Inferior/posterior AMI, use of β blockers, use of diuretics, single vessel disease, absence of reperfusion therapy, systolic blood pressure (sBP) at admission, and smoking. One point was given to sBP>128mmHg, 2 points to absence of reperfusion, and one point to other parameters. Sum of these points was calculated as the AF risk score (Table 1). AF occurred in 27.1% of patients with ≥5 points whereas it was observed 5.2% of those with <5 points. C-statistics of the risk score was 0.75 (95% CI 0.68–0.83).

Conclusion

We developed a novel risk score to estimate the risk of AF occurrence early after AMI, which can be a useful tool for the risk stratification after AMI.

Funding Acknowledgement

Type of funding sources: None.
Prognosis of low-flow low-gradient aortic valve stenosis with atrial fibrillation
Authors: Nishinarita R , Arao K , Sugisaki K , Yamashita T , Yozawa A , Kasahara T , Mase T
Published: October 2022

Background

Patients with Low-flow low-gradient (LFLG) aortic valve stenosis (AS) have possibly poor prognosis. Recently, it was reported that the LFLG AS patients have similar outcomes compared to high-gradient (HG) patients but worse outcomes compared to the normal-flow low-gradient [NFLG: SVi≥35 ml/m2, mPG <40mmHg] subgroup. The main determinant of LF state in severe AS patients with preserved LVEF are male gender, heart rate, LV volume and atrial fibrillation (AF). However, the relationship between the comorbidity with AF in LFLG AS and the risk of heart failure (HF) remains unclear.

Purpose

We elucidated about the prognosis of LFLG AS with AF.

Methods

We included 225 consecutive patients with severe AS (SAS, iAVA<0.6 cm2/m2) from 2013 to 2020. Among these patients, high-gradient SAS [HG-SAS; mean pressure gradient (mPG) ≥40 mmHg, n=88] and LFLG AS [stroke volume index (SVi) ≤35 ml/m2, mPG <40 mmHg, n=82] patients was extracted and the baseline characteristics including the presence or absence of AF were evaluated. The primary endpoint was worsening HF that required unplanned hospitalization or readjustment of HF drug therapy.

Results

Among patients with HG SAS and LFLG AS, worsening HF was observed in 65 patients. LFLG AS patients exhibited a higher oral rate of renin-angiotensin-system inhibitors (p=0.02). In addition, SVi and E/e' was lower in LFLG AS patients compared with HG SAS [SVi; 29.4 (24.4–34.0) versus 37.7 (28.2–45.3), p<0.0001, E/E'; 16.0 (13.1–21.5) vs 20.9 (16.0–27.4), p=0.002]. There is no differences between 2 groups in AF prevalence. Furthermore, 2 groups were subdivided as follow; HG SAS with AF (n=25), HG SAS without AF (n=63), LFLG AS with AF (n=24), LFLG AS without AF (n=58). The Kaplan Meier curves demonstrated LFLG SAS with AF experienced higher rate of worsening HF compared with HG SAS without AF and equivalent rate of worsening HF compared with HG SAS with AF (log rank, p<0.001). In the Cox hazard analysis among the LFLG AS patients, LFLG AS with paroxysmal AF (pAF, n=12) instead of chronic AF (cAF, n=12) showed a higher risk for worsening HF compared with those without AF (HR 5.0; 95% CI, 1.8–14; p=0.0028, HR 1.9; 95% CI, 0.62–5.8; p=0.26, respectively).

Conclusion

LFLG AS with AF exhibited a poor prognosis for HF compared with HG SAS without AF and equivalent rate of worsening HF compared with HG SAS with AF. Furthermore, the presence of pAf was associated with an increased risk of HF in patients with LFLF AS. Thus, intervention including drugs and catheter ablation for pAF in LFLG AS patients could lead to prevent worsening clinical outcomes.

Funding Acknowledgement

Type of funding sources: None.
Untreated sleep apnea and left atrial dilatation in patients with atrial fibrillation prior to catheter ablation
Authors: Tanaka N , Okada M , Tanaka K , Harada S , Kawahira M , Hirao Y , Onishi T , Koyama Y , Fujii K , Watanabe H , Okamura A , Iwakura K
Published: October 2022

Background

Sleep apnea and left atrial dilatation are both risk factors for an arrhythmia recurrence after catheter ablation (CA) of atrial fibrillation (AF). Negative intrathoracic pressure fluctuations during an obstructive apnea episode may cause the left atrium to distend and stretch its wall. Whether sleep apnea is associated with left atrial dilatation in patients receiving CA of AF remains unknown.

Purpose

We sought to elucidate whether moderate or severe untreated sleep apnea was associated with left atrial dilatation in patients with AF before CA.

Methods

This study was conducted under a retrospective, single-center, observational design. The data were derived from screening tests for sleep apnea, which were routinely performed in patients scheduled to receive CA of AF in our institution. After excluding patients who were already diagnosed with sleep apnea, we enrolled 1265 consecutive patients (age 65±11 years, 27.8% females, and 46.2% of non-paroxysmal AF) who underwent both home sleep apnea testing and multidetector computed tomography (MDCT) before the CA of AF. The severity of the sleep apnea was evaluated by the apnea-hypopnea index (AHI) using a watch-type peripheral arterial tonometry. Left atrial dilatation was evaluated by the left atrial maximum volume (LA max V) using 256-slice MDCT.

Results

The age was 65±11 years, 27.8% were females, and 46.2% had non-paroxysmal AF. The mean AHI was 20.3±15.3 and LA max V 105±34 ml (R2=0.075, p<0.0001). LA dilatation was defined by larger than mean LA max V (LA max V≥105 ml). We examined an LA max V≥105 ml as a predictor. After an adjustment by an advanced age (≥65 years), non-paroxysmal AF, male sex, obesity, hypertension, and congestive heart failure, all of which were significant predictors of an LA max V≥105ml in the univariate analysis, moderate or severe sleep apnea (AHI≥15) was a significant predictor of an LA max V≥105 ml (odds ratio 1.63, 95% confidence interval 1.24–2.14, p=0.0005).

Conclusion

Among the patients scheduled to receive catheter ablation of AF, moderate or severe sleep apnea was independently associated with left atrial dilatation.

Funding Acknowledgement

Type of funding sources: None.
Incidence and risk factors for residual adverse events despite anticoagulation in atrial fibrillation: results from phase II/III of the GLORIA-AF registry
Authors: Ding W Y , Lane D A , Gupta D , Huisman M V , Lip G Y H
Published: October 2022

Background

Residual risk of ischaemic stroke despite anticoagulation in patients with atrial fibrillation (AF) remains poorly investigated. We aimed to evaluate the incidence and risk factors for residual adverse events in AF.

Methods

Using data from phase II/III of the prospective GLORIA-AF registry, we studied anticoagulated patients from 935 centres across 38 participating who were consecutively enrolled with newly diagnosed AF and an increased risk of stroke (CHA2DS2-VASc ≥1). The primary outcome of interest was ischaemic stroke. Secondary outcomes were all-cause death, cardiovascular (CV) death and myocardial infarction. Risk factors for residual ischaemic stroke were identified using Cox proportional hazards analyses.

Results

22410 patients were included; median age 65 (IQR 71–78) and 10044 (44.8%) females. Over 3.0 (IQR 2.2–3.1) years, the incidence per 100-PYs of ischaemic stroke was 0.60 (95% CI, 0.54–0.67), all-cause death 3.22 (95% CI, 3.08–3.37), CV death 1.08 (95% CI, 1.00–1.16) and myocardial infarction 0.59 (95% CI, 0.53–0.66). Using multivariable Cox proportional hazards analysis, independent predictors of residual ischaemic stroke were age (HR 1.05 [95% CI, 1.03–1.06]), diabetes mellitus (HR 1.42 [95% CI, 1.09–1.85]), prior thromboembolism (HR 2.32 [95% CI, 1.79–3.00]), chronic obstructive pulmonary disease (HR 1.53 [95% CI, 1.04–2.26]) and use of anti-arrhythmic drugs (HR 0.70 [95% CI, 0.51–0.96]). The incidence of ischaemic stroke was comparable among patients treated with non-vitamin K antagonist oral anticoagulants vs. vitamin K antagonist; however, there were differences in the independent predictors between both groups.

Conclusion

Patients with AF remain at significant risk of ischaemic stroke despite anticoagulation therapy. Risk factors for residual ischaemic stroke were prior thromboembolism, age, persistent AF, diabetes mellitus, chronic obstructive pulmonary disease and non-use of anti-arrhythmic drug therapy. This emphasises the need to treat these risk factors, if modifiable, beyond antithrombotic therapy.

Funding Acknowledgement

Type of funding sources: None.
Impact of the atrial fibrillation better care pathway in clinically complex patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF General Long-Term Registry
Authors: Romiti G F , Proietti M , Vitolo M , Bonini N , Fawzy A M , Ding W Y , Fauchier L , Marin F , Nabauer M , Dan G A , Potpara T , Boriani G , Lip G Y H
Published: October 2022

Background

Clinical complexity is increasingly prevalent among patients with atrial fibrillation (AF). The “Atrial fibrillation Better Care” (ABC) pathway approach has been proposed to streamline a more holistic and integrated approach to AF care; however, there are limited data on its usefulness among clinically complex patients. We analyzed the impact of the ABC pathway in a contemporary cohort of clinically complex AF patients.

Methods

From the ESC-EHRA EORP-AF General Long-Term Registry, we analyzed clinically complex AF patients, defined as the presence of frailty (according to a 40-items Frailty Index), multimorbidity and/or polypharmacy. A K-medoids cluster analysis was performed to identify different groups of clinical complexity. The impact of an ABC-adherent approach on the risk of all-cause death, major adverse cardiovascular events (MACEs) and the composite outcome of all-cause death and MACE was analyzed through Cox-regression analyses, and delay of event (DoE) analyses; number needed to treat (NNT) was also estimated at 1 year of follow-up.

Results

Among 9,966 AF patients, 8,289 (92.3%) were clinically complex. Risk of all outcomes was higher among clinically complex patient. Adherence to the ABC pathway in the clinically complex group reduced the risk of all-cause death (adjusted HR [aHR]: 0.71, 95% CI 0.57–0.89), major adverse cardiovascular events (MACEs, aHR: 0.68, 95% CI 0.53–0.87) and composite outcome (aHR: 0.69, 95% CI: 0.57–0.84). Using cluster analysis, we identified a high clinical complexity group of AF patients. Adherence to the ABC pathway was associated with a significant reduction in the risk of death (aHR: 0.73, 95% CI 0.55–0.96) and composite outcome (aHR: 0.69, 95% CI 0.57–0.84) in the high-complexity cluster; similar trends were observed for MACEs. In DoE analyses, an ABC-adherent approach resulted in significant gains in event-free survival for all-cause death (Figure 1), MACEs, and composite outcome in clinically complex patients. Based on absolute risk reduction at 1 year of follow-up, the NNTs for ABC pathway adherence was 24 for all-cause death, 31 for MACEs and 20 for the composite outcome.

Conclusions

An ABC-adherent approach reduces the risk of major outcomes in clinically complex AF patients. Ensuring adherence to the ABC pathway is essential to improve clinical outcomes amongst clinically complex AF patients.

Funding Acknowledgement

Type of funding sources: Private company. Main funding source(s): Since the start of EORP, several companies have supported the programme with unrestricted grants.
The first Brazilian cardiovascular registry of atrial fibrillation: the primary results of the RECALL study
Authors: Lopes R D , Barros E Silva P G , Hoffmann Filho C R , Cavalvante M A , Miranda C M , Esper R B , De Lima G G , Ritt L E F , Silva R M F L , Nakazone M , Zimerman L I , De Souza O F , Fagundes A A , Saad E B , Teixeira R A
Published: October 2022

Background

There is limited prospective real-world evidence of patients with atrial fibrillation (AF) in Latin America.

Methods

The rationale and design of the study were previously published (1). Briefly, RECALL was the first nationwide prospective study of patients in Brazil with known atrial fibrillation. A total of 4,585 patients were included among 89 sites from April 2012 to August 2019. All patients were followed for one year by the protocol. Patient characteristics, medications under use and clinical outcomes during the follow-up were collected.

Results

From the total of patients enrolled, 41 were excluded from the analysis since they did not have a confirmed diagnosis of atrial fibrillation. The median age was 70 (61–78) years, 46% were women and the majority of the cases were permanent AF (53,8%). The mean CHA2DS2VASc was 3.2±1.6 and the median HASBLED was 2 [2–3]. The most common risk factor was arterial hypertension (77.9%). The median heart rate was 74 [65–85] and the mean ejection fraction was 52.2±2.6 (%). Only 4.4% of patients had history of previous ablation and 30.4% were using anti-arrhythmic. At baseline, 22.0% did not use anticoagulants (Figure 1) and 9.1% did not use any antithrombotic therapy. The most common anticoagulant was vitamin K antagonist – VKA (62.6%) while the remaining 37.4% were direct oral anticoagulants. The main reasons for not using an oral anticoagulant were physician judgment's (low risk of stroke – 24.6%) and difficult to control (14.7%) or perform INR (9.9%) while patient preference and adverse event represented respectively 5.3% and 4.1%, respectively. Only 42.5% of the INRs at baseline were between 2 and 3. During follow-up, the use of anticoagulants and INR in the therapeutic range increased to 87.1% and 59.1%, respectively. In one year, 17.8% of patients were hospitalized due to atrial fibrillation. At 1 year, the rates of death, stroke, systemic embolism and major bleeding were 5.76 [5.12–6.47], 2.77 [2.32–3.32] 1.01 [0.75–1.36], 2.21 [1.81–2.70], respectively. Among VKA users, the rate of mortality and bleeding was higher in the group with time in therapeutic range below 60% (Figure 2).

Conclusion

RECALL represents the largest prospective registry of patients with atrial fibrillation in Latin America. Our findings highlight important gaps in the treatment of patients which can inform clinical practice and help to guide future interventions to improve the care of these patients.

Funding Acknowledgement

Type of funding sources: Other. Main funding source(s): Brazilian Society of Cardiology
Left atrial cardiomyopathy and 10-year risk of Atrial Fibrillation
Authors: Uhe T , Stegmann T , Langhammer R , Laufs U , Dagres N , Wachter R
Published: October 2022

Background

Left atrial cardiomyopathy (LACMP) is considered a precursor or prerequisite of incident atrial fibrillation (AF). Various definitions including humoral, ECG- and echocardiographic parameters have been proposed, but not been rigorously and comparatively investigated and the role of excessive supraventricular ectopic activity (ESVEA) is poorly studied. We aimed to analyse the ten-year risk to develop AF in patients with cardiovascular risk factors and to define the impact of LACMP, its components and ESVEA on AF risk.

Methods

148 patients free of AF at baseline were followed for 10 years. Baseline examination included medical history, physical examination, echocardiography, 12-lead-ECG and 7-day-Holter ECG. LACMP was defined as either left atrial enlargement (left atrial volume index (LAVI) >35 ml/m2), P-terminal force in lead V1 (PTFV1) ≤ −4000 ms$cdot$μV or elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) >250 pg/ml. Firstly, we analyzed the association of these parameters on AF-free survival in Kaplan-Meier plots. Secondly, we repeated this analysis for ESVEA (defined as either >720 premature atrial contractions (PAC) per day or at least one atrial run >20 beats per day). Finally, parameters significantly associated with AF-free survival were included in a multivariable analysis to identify those independently predictive for AF.

Results

At baseline, eighty-nine patients fulfilled at least one criterion of LACMP while eight patients fulfilled all criteria. After ten years of follow-up, AF was newly detected in twelve patients (13.4%) with LACMP and two patients (3.4%) without LACMP (p=0.04). LAVI (p=0.005), ESVEA (p=0.016) and NT-proBNP (p=0.010) showed significant association with AF-free survival in univariate analysis while PTFV1 did not. In a combined Cox model of LACMP parameters, significant associations were found for log-transformed NT-proBNP (HR 3.56; 95% CI 1.33–5.31; p=0.04) and log-transformed PAC (HR 2.66; 95% CI 1.25–10.15; p=0.01) but not for LAVI and not for PTFV1.

Conclusion

The risk for AF is higher in patients with evidence of left atrial cardiomyopathy. NT-proBNP and premature atrial contractions independently predict AF-free survival. The role of supraventricular ectopic activity is underestimated and requires further study.

Funding Acknowledgement

Type of funding sources: None.
Linac-based stereotactic arrhythmia radioablation of paroxysmal atrial fibrillation in elderly patients
Authors: Di Monaco A , Gregucci F , Bonaparte I , Troisi F , Surgo A , Di Molfetta D , Vitulano N , Romanazzi I , Quadrini F , Carbonara R , Ludovico E , Guida P , Ciliberti M P , Fiorentino A , Grimaldi M
Published: October 2022

Background

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, occurring in 1–2% of the general population. Patients affected by AF have an increased risk of stroke and heart failure and European guidelines recommend catheter ablation of AF in symptomatic patients refractory to antiarrhythmic therapy. In elderly patients, the AF ablation procedure is associated with a higher rate of overall complications. Recently, stereotactic arrhythmia radioablation (STAR) with precise high-dose of radiation was used to treat ventricular arrhythmias.

Purpose

No data were reported in literature about the use of Linac-based STAR, so a prospective phase-II trial was designed to evaluate safety of Linac-based STAR in elderly patients with paroxysmal AF.

Methods

Fourteen patients (mean age 78±6 years; 57% male) were enrolled in the study. All patients had symptomatic paroxysmal AF refractory to antiarrhythmic drugs. All patients performed 1-week ECG-Holter monitoring (ECG-HM) and transthoracic echocardiogram before and after STAR. Primary end-point was defined as all the adverse events of special interest related to STAR treatment; secondary end-point was defined as AF recurrence after the treatment. The study was approved by the local Ethics Committee and all patients signed informed consent.

Results

All patients performed STAR with a mean overall treatment time of 3 minutes. No serious adverse events were documented acutely and after 6 months of follow up. Transthoracic echocardiogram did not show cardiac damage after STAR. The 1-week ECG-HM performed before STAR documented symptomatic AF episodes in all patients. The 1-week ECG-HM performed 1-month after procedure documented frequent symptomatic atrial ectopy and atrial tachycardias without AF recurrences. The 1-week ECG-HM performed 3 and 6 months after procedure did not revealed AF recurrences. Two patients had a single episode of sustained atrial tachycardia 6 months after STAR. Both patients performed a left atrial mapping using CARTO system and Pentaray mapping catheter documenting PV isolation without vein stenosis (figure); no phrenic nerve damage was documented in both patients. All patients had an improvement in quality of life.

Conclusion

Our preliminary data reported for the first time that the LINAC-based STAR approach could represent a valid alternative to perform PVI in elderly patients with paroxysmal AF.

Funding Acknowledgement

Type of funding sources: None.
Mobile health-technology integrated care in elderly atrial fibrillation patients: a report from the mAFA-II randomized clinical trial
Authors: Guo Y , Romiti G F , Proietti M , Bonini N , Zhang H , Lip G Y H
Published: October 2022

Background

The prospective Mobile Health Technology for Improved Screening and Optimized Integrated Care in AF (mAFA-II) randomized trial demonstrated the efficacy of a mobile health (mHealth) technology implemented “Atrial fibrillation Better Care” (ABC) pathway approach (mAFA intervention) for holistic or integrated care management in reducing the risk of adverse events in in patients with atrial fibrillation (AF). Whether these benefits also apply to elderly patients (who may be less adoptive of mHealth approaches) is unclear.

Purpose

In this ancillary analysis of the mAFA-II trial, we evaluated the effect of the mAFA intervention among elderly AF patients (age ≥75 years).

Methods

The mAFA-II trial enrolled adults AF patients across 40 centres in China between June 1, 2018 and August 16, 2019. The main outcome was the composite outcome of stroke or thromboembolism, all-cause death, and rehospitalization. Effect of the mAFA intervention was assessed through Cox proportional hazard models after the adjustment for baseline risk factors and cluster effect. We also assessed the interaction between age and the mAFA intervention effect on the main trial population.

Results

In this analysis, 1,163 elderly AF patients (mean age: 82.6±5.3 years, 43.1% females) were included, of which 520 were allocated to mAFA intervention and 643 to usual care. The mAFA intervention was associated with a significant reduction of the composite outcome (adjusted hazard ratio [aHR]: 0.58, 95% CI: 0.35–0.97) and rehospitalizations alone (aHR: 0.47, 95% CI: 0.24–0.91). A significant interaction between age and mAFA allocation group was observed for both the composite outcome (p=0.002; Figure 1, Panel A) and rehospitalization alone (p=0.015; Figure 1, Panel B), with the beneficial effect of the mAFA intervention decreasing with increasingly higher age, particularly at age ≥80 years old.

Conclusions

A mHealth-technology implemented ABC pathway is effective in reducing adverse clinical events in older AF patients aged ≥75 years old. The benefits obtained with mAFA intervention were attenuated at extreme ages, especially in those aged ≥80 years old.

Funding Acknowledgement

Type of funding sources: Public Institution(s). Main funding source(s): This research was funded by the National Natural Science Foundation of China 82170309). This study was an investigator-initiated project, with limited funding by independent research and educational grants.
Intravenous vagal stimulation catheter, JOHAKU, rapidly decreases heart rate and myocardial oxygen consumption without worsening hemodynamics
Authors: Yokota S , Kakuuchi M , Yokoi A , Kawada T , Uemura K , Ishida E , Sakamoto K , Todaka K , Saku K
Published: October 2022

Background

Rapid reduction of heart rate (HR) is the most evident physiological response of vagal nerve stimulation (VNS). Since HR reduction is the most potent factor to decrease myocardial oxygen consumption rate (MVO2), the appropriate VNS can exert cardio-protective effects. It is also known that VNS reduces inflammation, oxidative stress, and sympathetic overload. In addition, the VNS during ischemia-reperfusion is known to attenuate myocardial damage by studies in various animal species. Despite the presence of preclinical evidence of VNS benefits, the lack of the device has limited the translation of this technology to clinical practice. We have recently developed an intravenous VNS catheter (JOHAKU, Neuroceuticals Inc.) that can stimulate the right vagal nerve via superior vena cava (SVC) (Figure 1) on temporary basis.

Purpose

We aimed to confirm the feasibility of JOHAKU as a device to modulate heart rate and MVO2 rapidly by a canine experiment.

Methods

In eight beagle dogs, JOHAKU was inserted from the right femoral vein and placed at the SVC level. The stimulation intensity was adjusted to 10–20 V (20 Hz). We simultaneously recorded electrocardiogram and intraarterial blood pressure (BP). In three of eight dogs, we measured the left anterior descending coronary artery flow and oxygen saturations of arterial and coronary sinus blood to calculate MVO2. We compared HR, BP, and MVO2 during JOHAKU stimulation to ones at baseline.

Results

As shown in Figure 2, JOHAKU attenuated HR immediately after stimulation. Compared with baseline, JOHAKU significantly reduced HR (baseline: 135±13 vs. 5 min on stimulation: 107±13 bpm, p<0.05), and did not affect mean BP significantly (96.2±22.8 vs. 89.4±26.6 mmHg, P=0.59). HR promptly recovered to baseline level after JOHAKU stopped. JOHAKU also reduced MVO2 (0.57±0.43 vs. 0.48±0.38 ml/min, p<0.05).

Conclusion

JOHAKU rapidly attenuated cardiac metabolism burden via the rapid HR reduction. The controllability of HR by JOHAKU without affecting BP enables us to apply the VNS even for patients with hemodynamic instability, such as heart failure and acute myocardial infarction.

Funding Acknowledgement

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Japan Agency for Medical and Research Development
Holistic approach of ablation versus antiarrhythmic drugs for efficacy, safety, and quality of life improvement in rhythm control of atrial fibrillation: a meta-analysis of randomized trials
Authors: Prana Jagannatha G , Putra Swi Antara I M , Surya Pradnyana I W A , Kamardi S
Published: October 2022

Background/Introduction

Recent studies have shown that catheter ablation (CA) is more superior compared to the usage of the antiarrhythmic drug (AAD) regarding its efficacy in decreasing the incidence of persistent and chronic atrial fibrillation (AF). However, choosing the right rhythm control strategy to provide holistic care for the patients should be individualized on each patients condition.

Purpose

In this meta-analysis, the author will compare both CA and AAD regarding their efficacy, safety, and their effect on the quality of life of AF patients.

Methods

The authors systematically searched the relevant journals throughout PubMed, Medline, and the Cochrane Library, with a range of publications from 2010 to 2021. The primary outcomes were AF recurrence, quality of life score, and adverse events. Secondary outcomes were the rehospitalization rate and all-cause mortality. Analysis was performed using a random-effects model with the Mantel-Haenszel method, and results are presented as 95% CIs.

Results

A total of 23 RCTs consisted of 10,316 patients were included. Although some adverse events (pericarditis, pleural effusions, and cardiac tamponade) were found in 2.8% population of the CA group (RR: 4.15; 95% CI: 1.65, 10.41; p=0.002), the CA group was found superior in suppressing the rate of AF recurrence (RR: 0.56; 95% CI: 0.48, 0.65; p<0.00001). Regarding the SF-36 Mental (p<0.00001) and Physical Assessment (p<0.0001), both CA and AAD showed increased quality of life post treatment compared with baseline level (pre-treatment) for each therapy. Following the interventions, the CA group significantly showed a lower rehospitalization rate (RR: 0.82; 95% CI: 0.70,0.97; p=0.02) and also showed a lessened mortality trend (6.84%) compared to the AAD group (9.01%) even though not statistically significant.

Conclusion(s)

Statistically, there is no difference for both groups in their capability of reducing the mortality rate. However, CA was found to be more superior in efficacy and reducing the number of rehospitalizations. Quality of life also significantly improve same as AAD, which further might be provide a holistic outcome of rhytm control.

Funding Acknowledgement

Type of funding sources: None.
Impact of high-power and very high-power short-duration radiofrequency ablation on procedure characteristics and first-pass isolation during pulmonary vein isolation
Authors: Sallo Z , Perge P , Orban G , Piros K , Herczeg S Z , Nagy K V , Abraham P , Osztheimer I , Merkely B , Geller L , Szegedi N
Published: October 2022

Introduction

High-power short-duration (HPSD) radiofrequency ablation has been proposed as a method for producing rapid and effective lesions for pulmonary vein isolation (PVI). We aimed to evaluate the procedural characteristics and the first-pass isolation (FPI) rate of HPSD and very high-power short-duration (vHPSD) ablation compared to low-power long-duration (LPLD) ablation technique.

Methods

156 patients with atrial fibrillation (AF) were enrolled and assigned to LPLD, HPSD, or vHPSD PVI. The energy setting was 30W, 50W, and 90W in the LPLD, HPSD, and vHPSD groups, respectively.

Results

Bilateral PVI was achieved in all cases. The procedure time was 85 [75–101] min, 79 [65–91] min, and 70 [53–83] min in the LPLD, HPSD, and vHPSD groups, respectively (p<0.0001). Left atrial (LA) dwelling times were also decreased significantly with the increase of RF energy (61 [55–70] min, 53 [41–56] min, and 45 [34–52] min, in the LPLD, HPSD, and vHPSD groups, respectively, p<0.0001). The total RF ablation time was 1567 [1366–1761] sec, 1398 [1021–1711] sec, and 336 [247–386] sec in the LPLD, HPSD, and vHPSD group, respectively (p<0.0001). The bilateral FPI rate was 57%, 78%, and 80% in the LPLD, HPSD, and vHPSD groups, respectively (p=0.0097). On the left side, FPI was achieved in 66% in the LPLD, 92% in the HPSD, and 85% in the vHPSD ablation group (p=0.0015). FPI on the right side was achieved in 72% in the LPLD, 88% in the HPSD, and 88% in the vHPSD ablation group (p=0.0188). The univariate analysis revealed that the use of HPSD (both sides: OR=2.72, 95% CI 1.15–6.44, p=0.023; right side: OR=2.90, 95% CI 1.02–8.20, p=0.045; left side: OR=5.91, 95% CI 1.84–19.04, p=0.003) and vHPSD (both sides: OR=2.90, 95% CI 1.24–6.44, p=0.014; right side: OR=3.09, 95% CI 1.09–8.74, p=0.045; left side: OR=2.89, 95% CI 1.13–7.43, p=0.027) ablation techniques were associated with a higher probability of FPI. The mid-term arrhythmia-free survival was similarly high in all three groups.

Conclusion

Our prospective, observational cohort study showed that both HPSD and vHPSD RF ablation is effective, as it shortens procedure time and RF time and results in a higher rate of FPI compared to LPLD ablation. Moreover, the mid-term arrhythmia-free survival was similarly high in all three groups. In our study, no safety concerns were raised for HPSD or vHPSD ablation.

Funding Acknowledgement

Type of funding sources: None.